Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation

<p>Refractory pruritus associated with Essential Thrombocythemia (ET) is rare. Herein, we present the first report of resistant pruritus responsive to ruxolitinib in an ET patient with a calreticulin mutation.</p>

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kubra Cerci (Auteur), Pusem Patir (Auteur)
Format: Livre
Publié: Global Journal of Medical and Clinical Case Reports - Peertechz Publications, 2023-01-25.
Sujets:
Accès en ligne:Connect to this object online.
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_2455-5282_000167
042 |a dc 
100 1 0 |a Kubra Cerci  |e author 
700 1 0 |a Pusem Patir  |e author 
245 0 0 |a Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation 
260 |b Global Journal of Medical and Clinical Case Reports - Peertechz Publications,   |c 2023-01-25. 
520 |a <p>Refractory pruritus associated with Essential Thrombocythemia (ET) is rare. Herein, we present the first report of resistant pruritus responsive to ruxolitinib in an ET patient with a calreticulin mutation.</p> 
540 |a Copyright © Kubra Cerci et al. 
546 |a en 
655 7 |a Case Study  |2 local 
856 4 1 |u https://doi.org/10.17352/2455-5282.000167  |z Connect to this object online.